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A B S T R A C T
Purpose
Figitumumab (CP-751,871), a fully human immunoglobulin G2 monoclonal antibody, inhibits the
insulin-like growth factor 1 receptor (IGF-1R). Our multicenter, randomized, phase III study
compared figitumumab plus chemotherapy with chemotherapy alone as first-line treatment in
patients with advanced non–small-cell lung cancer (NSCLC).
Patients and Methods
Patients with stage IIIB/IV or recurrent NSCLC disease with nonadenocarcinoma histology
received open-label figitumumab (20 mg/kg) plus paclitaxel (200 mg/m2) and carboplatin (area
under the concentration-time curve, 6 mg  min/mL) or paclitaxel and carboplatin alone once every
3 weeks for up to six cycles. The primary end point was overall survival (OS).
Results
Of 681 randomly assigned patients, 671 received treatment. The study was closed early by an
independent Data Safety Monitoring Committee because of futility and an increased incidence of
serious adverse events (SAEs) and treatment-related deaths with figitumumab. Median OS was
8.6 months for figitumumab plus chemotherapy and 9.8 months for chemotherapy alone (hazard
ratio [HR], 1.18; 95% CI, 0.99 to 1.40; P  .06); median progression-free survival was 4.7 months
(95% CI, 4.2 to 5.4) and 4.6 months (95% CI, 4.2 to 5.4), respectively (HR, 1.10; P  .27); the
objective response rates were 33% and 35%, respectively. The respective rates of all-causality
SAEs were 66% and 51%; P  .01). Treatment-related grade 5 adverse events were also more
common with figitumumab (5% v 1%; P  .01).
Conclusion
Adding figitumumab to standard chemotherapy failed to increase OS in patients with
advanced nonadenocarcinoma NSCLC. Further clinical development of figitumumab is not
being pursued.
J Clin Oncol 32:2059-2066. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Metastatic non–small-cell lung cancer (NSCLC) is
rarely curable and, despite significant treatment ad-
vances over the last decade, 5-year survival rates
remain below 5%.1 Current therapeutic options
include histology-based chemotherapy, antiangio-
genic agents, and targeted agents inhibiting
epidermal growth factor receptor and anaplastic
lymphoma kinase. Insulin-like growth factor 1
(IGF-1) receptor (IGF-1R) is a central component
of cancer signal transduction pathways.2 Expression
of IGF-1R is detectable in 39% to 84% of advanced
NSCLCs and is more frequently found in squamous
cell lung cancer.3 The prognostic significance of
IGF-1R expression remains unclear. Several pro-
spective studies suggest a relationship between cir-
culating IGF-1 and cancer risk.4,5
Figitumumab (CP-751,871) is a fully human
immunoglobulin G2 monoclonal antibody that in-
hibits IGF-1R. In phase I trials, it was well tolerated
as a single agent and in combination with chemo-
therapy at 20 mg/kg every 3 weeks.6,7 In a random-
ized phase II study of patients with treatment-naive
advanced NSCLC, the originally reported objective
response rate (ORR) was 54% with figitumumab 10
or 20 mg/kg plus full-dose paclitaxel and carbopla-
tin, and 42% with chemotherapy alone. Median
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progression-free survival (PFS) was initially reported as 5.0 months
with figitumumab 20 mg/kg and 3.5 months with chemotherapy
alone. No unexpected toxicities were observed. These findings
prompted a prospective, randomized phase III trial of figitumumab
plus paclitaxel and carboplatin compared with chemotherapy alone as
first-line treatment for advanced NSCLC. However, the phase II data
were subsequently retracted after a reanalysis revealed a lower ORR in
both treatment arms (see Discussion).8
In this article, we report the results of the phase III trial, which was
restricted to patients with nonadenocarcinoma histology based on an
initial analysis of the phase II study that indicated potentially increased
figitumumab efficacy in this subset.8
PATIENTS AND METHODS
Patients
Eligible patients were at least 18 years old with histologically or cytolog-
ically confirmed advanced NSCLC; documented American Joint Committee
on Cancer9 stage IIIB or metastatic (stage IV or recurrent) disease not amena-
ble to curative treatment; and a primary histology of predominantly squamous
cell, large cell, or adenosquamous carcinoma. Prior systemic treatment for
NSCLC and previous or concurrent therapy with IGF-1R inhibitors or growth
hormone agonists or antagonists were prohibited. Adjuvant chemotherapy
was permitted if completed at least 12 months before randomization. Prior
surgery or radiation therapy was permitted if completed at least 3 weeks before
randomization, with all acute toxicities resolved to National Cancer Institute
Common Terminology Criteria for Adverse Events version 3.0 grade 1. Pa-
tients had to have an Eastern Cooperative Oncology Group performance
status of 0 or 1 and adequate organ function. Exclusions included symptom-
atic CNS metastases, other active malignancies, uncontrolled hypertension, or
uncontrolled diabetes (baseline glycosylated hemoglobin [HbA1c] 8%).
The study was conducted in accordance with International Conference
on Harmonisation Good Clinical Practice guidelines, the declaration of Hel-
sinki, and local regulatory requirements and laws. Institutional review board
or independent ethics committee approval was required for each investigator
and center. Written informed consent was obtained from all patients.
Study Design and Treatment
Patients were randomly assigned in a 1:1 ratio to open-label figitu-
mumab plus paclitaxel and carboplatin (investigational arm) or paclitaxel
and carboplatin alone (control arm), stratified by previous adjuvant chem-
otherapy, sex, and histology (squamous-cell v combined large-cell or ade-
nosquamous cancer).
The primary end point was overall survival (OS), which was defined as
time from randomization to death as a result of any cause. Secondary end
points included PFS, ORR, and safety. The association between serum IGF-1
levels and OS was a preplanned exploratory objective.
All patients received carboplatin (area under the concentration-time
curve, 6 mg  min/mL) and paclitaxel (200 mg/m2) intravenously on day 1 once
every 3 weeks for up to six cycles. In the investigational arm, patients also
received figitumumab 20 mg/kg intravenously on day 1 of each 3-week cycle,
for up to 17 cycles (approximately 1 year of treatment).
On the investigational arm, if paclitaxel and/or carboplatin were discon-
tinued early, patients could continue single-agent figitumumab (once every 3
weeks) until disease progression or intolerance. Additional cycles were permit-
ted in patients exhibiting response, based on agreement between the study
sponsor and investigator. If figitumumab was discontinued, paclitaxel and
carboplatin were continued for a maximum of six cycles until disease progres-
sion or intolerance. Standard supportive therapies were instituted in both
arms. Guidelines for managing emergent hyperglycemia were provided,
including immediate treatment, protocol-defined figitumumab-dosage
modification, and continued oral glucose-lowering therapy if hyperglycemia
was expected to continue.
Study Procedures
Tumor assessment was performed at baseline and every 6 weeks until
radiologic disease progression or initiation of subsequent anticancer therapy
using Response Evaluation Criteria in Solid Tumors version 1.0.10 Adverse
events were graded using National Cancer Institute Common Terminology
Criteria for Adverse Events version 3.0. Clinical assessments, including hema-
tology and serum chemistry, were performed at baseline, on day 1 of cycle 1 (all
measurements), days 8 and 15 of cycle 1 (hematology only), on day 1 of each
subsequent cycle, and at the end of treatment. Levels of HbA1c were measured
at baseline, before cycle 4, and at the end of treatment.
Serum samples were collected within 2 hours before chemotherapy
and/or figitumumab infusion at cycles 1 and 4 and at the end of treatment.
Total IGF-1 levels were determined by immunochemiluminometric assay at
MDS Pharma Services (now LabCorp; Mississauga, Ontario, Canada). An
independent Data Safety Monitoring Committee (DSMC) monitored safety
and efficacy.
Statistical Analysis
With one-sided .025 level testing and 90% power, 820 patients were
needed to detect a 30% improvement for figitumumab plus chemotherapy
over the median 10-month survival rate seen with paclitaxel plus carboplatin
therapy (hazard ratio [HR], 0.77); 649 events were expected at full follow-up.
The primary assessment was a log-rank test stratified by factors used in ran-
domization. The analysis set included all randomly assigned patients on an
intent-to-treat basis. Two-sided P values were determined.
Two interim analyses were planned after approximately one third and
two thirds of the anticipated number of events had occurred. A Lan-DeMets
spending function approach with O’Brien-Fleming stopping bounds (Appen-
dix Table A1 [online-only]) was used to reject the null hypothesis (efficacy
boundary) and the alternative hypothesis (futility boundary). Statistical anal-
yses were conducted by Pfizer.
RESULTS
Patients and Treatment Exposure
Between April 2008 and September 2009, 681 patients from 163
sites in 25 countries were randomly assigned and 671 received treat-
ment (figitumumab group, 338; control group, 333; Fig 1). Demo-
graphic and baseline characteristics were well balanced between
treatment arms (Table 1). Patients’ median age was 62 years. Most of
the patients were men and most had stage IV disease. Patients in the
figitumumab and control arms received a median of four and five
cycles of chemotherapy, respectively (Table 2); 33% and 44%, respec-
tively, completed six cycles of paclitaxel, and 34% and 46% completed
six cycles of carboplatin. Figitumumab-treated patients received a
median of four figitumumab cycles; 109 (32%) of 338 figitumumab-
treated patients received four to six cycles, seven (2%) of 338 patients
received 17 cycles, and four (1%) of 338 received more than 20 cycles.
A total of 124 (37%) of 338 patients received figitumumab after
completing or discontinuing chemotherapy (median of two mainte-
nance cycles). Of these, 87 (26%) of 338 patients received figitu-
mumab maintenance after six cycles (maintenance therapy could start
earlier than cycle 6).
On DSMC advice, enrollment was suspended in September 2009
because of a higher number of serious adverse events (SAEs) and
deaths in the figitumumab arm. The study was permanently closed to
new accrual in December 2009, after the first interim analysis indi-
cated that the addition of figitumumab was highly unlikely to meet the
primary end point of improving OS over chemotherapy alone.
Follow-up for OS continued until March 2011. The overall median
follow-up time was 23.1 months (Table 3).
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Efficacy
At the final analysis, 259 patients in the figitumumab arm and
251 in the control arm had died (Table 3). The median OS was 8.6
months (95% CI, 7.4 to 9.3) and 9.8 months (95% CI, 8.6 to 10.9),
respectively (HR, 1.18; 95% CI, 0.99 to 1.40; P .06; Fig 2A). Respec-
tive 1-year survival rates were 34% and 39%. The effect of figitu-
mumab was similar across all subgroups based on demographic or
other baseline characteristics (Fig 3).
Median PFS was 4.7 months for the figitumumab arm (95% CI,
4.2 to 5.4) and 4.6 months for the control arm (95% CI, 4.2 to 5.4; HR,
1.10; 95% CI, 0.93 to 1.32; P  .27; Fig 2B). Respective ORRs were
33% (95% CI, 28 to 38) and 35% (95% CI, 29 to 40; Table 3).
Safety
Alopecia and nausea were the most common treatment-
emergent (all-causality) adverse events (AEs) of any grade and
occurred in a similar number of patients in each arm (Table 4).
Any-grade AEs that occurred more frequently in the figitumumab
arm included hyperglycemia, diarrhea, decreased appetite, vomiting,
and decreased weight. Grade 3/4 AEs that occurred more frequently in
the figitumumab arm included hyperglycemia, decreased appetite,
dehydration, diarrhea, fatigue, and nausea.
Treatment-emergent (all-causality) SAEs occurred in 66% of the
figitumumab arm and 51% of the control arm (P  .01 by Fisher’s
exact test). Excluding disease progression, the most common SAEs
were pneumonia (6% v 4%, respectively), dehydration (4% v 1%),
asthenia (3% v 1%), and hyperglycemia (3% v 1%). The SAEs were
judged to have a reasonable possibility of being treatment-related in
22% and 12% of patients, respectively.
Nonprogression grade 5 AEs occurred in 13% of the figitu-
mumab arm and 10% of the control arm (P .22). The most com-
mon grade 5 AEs in the figitumumab arm were pulmonary
hemorrhage and pneumonia (2% each; Appendix Table A2). Grade 5
AEs were considered to be treatment-related in 5% of the
Randomly assigned, stratified by previous adjuvant chemotherapy,
sex, and histology (squamous cell v combined large cell or adenosquamous)
(N = 681)
Figitumumab arm
  Allocated to figitumumab plus chemotherapy  (n = 342)
    Received figitumumab plus chemotherapy  (n = 338)
    Did not receive figitumumab plus chemotherapy  (n = 3)
*)1 = n( yparehtomehc ylno devieceR    
Control arm
)933 = n( yparehtomehc ot detacollA  
)233 = n( yparehtomehc devieceR    
)7 = n( yparehtomehc eviecer ton diD    
)243 = n( ycaciffe rof dezylanA
Analyzed for safety
)833 = n( stneve esrevdA  
)433 = n( atad yrotarobaL  
)4 = n( ffotuc atad retfa pu-wolloF
)2 = n( bamumutigif deunitnocsiD
)1 = n( htaed dna noissergorp evitcejbO  
  Transition to off-study, single-patient IND (n = 1)
)933 = n( ycaciffe rof dezylanA
Analyzed for safety
)333 = n( stneve esrevdA  
)423 = n( atad yrotarobaL  
Receiving figitumumab at time of data cutoff (n = 2)
Receiving chemotherapy at time of data cutoff (n = 0)
)633 = n( bamumutigif deunitnocsiD
)34 = n( htaeD
)22 = n( bamumutigif ot detaler EA
)23 = n( bamumutigif ot detalernu EA
)01 = n( noitaroireted htlaeh labolG
)2 = n( pu-wollof ot tsoL
)071 = n( espaler ro noissergorp evitcejbO
)22 = n( rehtO
)1 = n( noitaloiv locotorP
)43 = n( EA ot detalernu lasufer tneitaP
)902 = n( yparehtomehc deunitnocsiD
)04 = n( htaeD
)92 = n( yparehtomehc ot detaler EA
)72 = n( yparehtomehc ot detalernu EA
)9 = n( noitaroireted htlaeh labolG
)2 = n( pu-wollof ot tsoL
)87 = n( espaler ro noissergorp evitcejbO
)5 = n( rehtO
)1 = n( noitaloiv locotorP
)81 = n( EA ot detalernu lasufer tneitaP
)921 = n( yparehtomehc detelpmoC
Receiving chemotherapy at time of data cutoff (n = 0)
)1 = n( bamumutigif deunitnocsiD
AE unrelated to figitumumab (patient was randomly (n = 1)
assigned to figitumumab arm but received only 
paclitaxel and carboplatin)
)681 = n( yparehtomehc deunitnocsiD
)23 = n( htaeD
)13 = n( yparehtomehc ot detaler EA
)31 = n( yparehtomehc ot detalernu EA
)01 = n( noitaroireted htlaeh labolG
)1 = n( pu-wollof ot tsoL
)18 = n( espaler ro noissergorp evitcejbO
)8 = n( rehtO
)1 = n( noitaloiv locotorP
)9 = n( EA ot detalernu lasufer tneitaP
)741 = n( yparehtomehc detelpmoC
Fig 1. CONSORT diagram. (*) Patient analyzed in control arm for safety. AE, adverse events; IND, investigational new drug.
Figitumumab Alone or With Paclitaxel and Carboplatin in NSCLC
www.jco.org © 2014 by American Society of Clinical Oncology 2061
from 130.192.222.19
Information downloaded from jco.ascopubs.org and provided by at Bibl.Centralizzata medicina e chirurgia on August 4, 2016
Copyright © 2014 American Society of Clinical Oncology. All rights reserved.
figitumumab arm and 1% of the control arm (P .01). With figitu-
mumab, these grade 5 AEs included hemoptysis, pneumonia, un-
known cause reported only as death, septic shock, cardiorespiratory
arrest, decrease of performance status, neutropenic sepsis, toxicity to
various agents, renal failure, hemorrhage, and hypovolemic shock
( 1% each). In the control arm, the grade 5 AEs included unknown
cause reported as death, pneumonia, septic shock, and dehydration
( 1% each).
Figitumumab was discontinued because of treatment-related
AEs in 7% of patients, and chemotherapy was discontinued for this
reason in 9% of patients in each arm.
Relationship of Total IGF-1 and HbA1c to Outcomes
For the exploratory analysis of outcomes based on baseline total
IGF-1, a cutoff of 120 ng/mL was selected because it was associated
with the largest observed differences in treatment effect above and
below it. Baseline IGF-1 was not related to overall frequency or nature
of AEs. However, grade 5 AEs were more common among
figitumumab-treated patients with baseline IGF-1 levels less than 120
ng/mL (56%) than among those with baseline levels of 120 ng/mL or
higher (38%) and those in the control arm (37% and 36% in the low
and high IGF-1 groups, respectively). In the figitumumab arm, me-
dian OS for patients with low and high baseline IGF-1 was 7.0 months
and 10.4 months, respectively; in the control arm it was 10.1 and 9.4
months, respectively (Appendix Fig A1). For patients with high IGF-1,
there was no difference in OS between treatment groups (HR, 0.93;
P  .67). For those patients with low IGF-1, OS was significantly
shorter in the figitumumab arm (HR, 1.37; P .01).
The rate of all-causality AEs did not vary markedly by baseline
HbA1c status, but the rate of grade 3/4 AEs for patients with no grade
5 events was slightly lower in those with baseline levels less than 5.7%
than in those with levels  5.7% (figitumumab arm, 30% v 36%;
control arm, 33% v 35%). Median OS in patients with low baseline
HbA1c was 8.7 months in the figitumumab arm and 10.2 months in
the control arm (HR, 1.07; P .65). The respective values in patients
with high HbA1c were 8.2 and 9.7 months (HR, 1.26; P .05).
DISCUSSION
This was the first randomized phase III study to test whether combin-
ing an IGF-1R inhibitor (figitumumab) with paclitaxel and carbopla-
tin could improve OS versus chemotherapy alone as first-line
treatment for advanced nonadenocarcinoma NSCLC. When this trial
was initiated, IGF-1R was thought to play an important role in squa-
mous cell histology NSCLC, an area of particular unmet need. Unex-
pectedly, adding figitumumab to chemotherapy proved deleterious.
The DSMC closed the study because of therapeutic futility and in-
creased SAEs, including treatment-related deaths, in the figitumumab
arm. This outcome was disappointing given the originally reported
phase II ORR of 54% for combination therapy compared with 42% for
chemotherapy alone.8
The phase III study was designed and conducted in good faith
based on the aforementioned phase II trial findings in treatment-naive
advanced NSCLC. Following closure of the phase III trial, the phase II
data were retracted after a reanalysis revealed a lower ORR in both
treatment arms.8 In addition, median PFS no longer trended in favor
of figitumumab (4.5 months with figitumumab 20 mg/kg and 4.3
months with chemotherapy alone). The heightened toxicity of figitu-
mumab in the phase III trial was not observed in the original phase I/II
trials in NSCLC, which enrolled more than 150 patients in total. In our
current study, the figitumumab combination failed to improve any
efficacy end points over chemotherapy alone. Overall survival, the
primary end point, was 8.6 months versus 9.8 months respectively.
The ORR with figitumumab (33%) was similar to that observed in the
phase II final analysis (37% in both the overall cohort [initially re-
ported as 54%] and the nonadenocarcinoma cohort). Another ad-
vanced NSCLC trial, initiated after the phase III was underway, used
the same treatment in combination with figitumumab and the ORR
was 39%.12
Subgroup analysis suggests that figitumumab safety and tolera-
bility were poorer in patients with low baseline IGF-1 ( 120 ng/mL)
compared with those with high IGF-1 ( 120 ng/mL), particularly
Table 1. Baseline Patient Characteristics
Characteristic
Figitumumab Arm
(n  342)
Control Arm
(n  339)
No. of
Patients %
No. of
Patients %
Sex
Male 261 76 260 77
Female 81 24 79 23
Age, years
Median 62 62
Range 30-90 36-83
Ethnicity
White 265 78 270 80
Asian 56 16 59 17
Black 9 3 4 1
Other 12 4 6 2
ECOG performance status
0 113 33 115 34
1 226 66 217 64
Not reported 3 1 7 2
Current disease stage
Stage IIIB 39 11 39 12
Stage IV 302 88 300 88
Not reported 1  1 0
Smoking status
Never smoked 34 10 33 10
Current smoker 142 42 141 42
Former smoker 166 49 165 49
Histology
Squamous cell 295 86 289 85
Large cell 28 8 26 8
Adenosquamous 15 4 19 6
Other 4 1 5 1
Prior treatments
Surgery 72 21 61 18
Radiation 44 13 36 11
Adjuvant chemotherapy† 14 4 15 4
NOTE. Data are presented for all patients by randomized arm. The stratification
factors (histology, sex, and adjuvant chemotherapy) are presented as collected in the
case report forms rather than as collected by the randomization system.
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
TNM Classification of Malignant Tumours (6th ed).11
†Systemic therapy included carboplatin/paclitaxel (n  3), cisplatin/vinorel-
bine (n  7), cisplatin/gemcitabine (n  4), carboplatin/gemcitabine (n  3),
cisplatin/etoposide (n  3), other regimens with carboplatin (n  3), other
regimens with cisplatin (n  4), and other nonplatinum regimens (n  2).
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with respect to grade 5 AEs. Consequently, in the figitumumab arm,
median OS was shorter in patients with low IGF-1 compared with
those with high IGF-1 and was significantly shorter compared with
control patients who had low IGF-1 (HR, 1.37, P  .01). Although
additional studies are required, these data suggest that low baseline
total IGF-1 may be a safety biomarker that identifies a subset of
patients for whom IGF-1R inhibition is particularly harmful. In a
phase I study of ganitumab, a human monoclonal antibody against
IGF-1R, treatment transiently increased IGF-1.13 Low baseline IGF-1
may indicate an inability to mount a compensatory increase in IGF-1
and greater likelihood of AEs.
Hyperglycemia of any grade occurred more frequently in the figitu-
mumab arm than in the control arm (23% v 5%), as did grade 3/4
hyperglycemia(12%v1%).Hyperglycemiawasoneofthemostcommon
SAEs, with greater frequency in the figitumumab arm than in the control
arm. Hyperglycemia is likely a class effect stemming from impaired ho-
meostatic control of glucose metabolism as a consequence of IGF-1R
inhibition.14 Hyperglycemia was rarely severe and was usually manage-
able with agents such as metformin, but could have contributed in subtle
ways to increased toxicity in the figitumumab arm.
Baseline HbA1c was not a strong biosafety marker, although
grade 3/4 AEs were slightly more common in patients with levels
Table 2. Study Drug Exposure
Treatment Delivery
Figitumumab Arm (n  338) Control Arm (n  333)
Figitumumab Paclitaxel Carboplatin Paclitaxel Carboplatin
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
Cycles started
Median 4 4 4 5 5
Range 1-52† 1-6 1-6 1-6 1-6
Duration of treatment, weeks
Median 12.1 10.2 10.2 12.3 12.6
Range 0.1-161.3† 0.1-20.1 0.1-20.1 0.1-23 0.1-23
Patients with at least one dose reduction 30 9 55 16 51 15 52 16 44 13
Patients with at least one dose delay 76 22 52 15 54 16 42 13 42 13
Abbreviation: IND, investigational new drug.
Patients in the chemotherapy arm who received carboplatin, n  332.
†Includes experience after data cutoff from the last ongoing patient, who transitioned to single patient IND in September 2012.
Table 3. Efficacy Results
End Point
Figitumumab Arm (n  342) Control Arm (n  339)
Hazard Ratio PNo. of Patients % No. of Patients %
Median follow-up time, months 23.3 22.8
Overall survival (primary end point) .06
Patient deaths 259 76 251 74
Median, months† 8.6 9.8 1.18‡
95% CI 7.4 to 9.3 8.6 to 10.9 0.99 to 1.40
One-year survival§ 34 39
Progression-free survival (investigator assessment) .27
Events 261 76 241 71
Objective progression 206 60 197 58
Death without objective progression 55 16 44 13
Median, months† 4.7 4.6 1.10
95% CI 4.2 to 5.4 4.2 to 5.4 0.93 to 1.32
Best overall response (investigator assessment)¶ .68
Complete response 2 0.6 3 0.9
Partial response 111 32 114 34
Stable disease 126 37 120 35
ORR 33 35
95% exact CI 28 to 38 29 to 40
Abbreviation: ORR, objective response rate.
Two-sided stratified log-rank test.
†Brookmeyer and Crowley method.
‡Stratified Cox proportional hazards model v arm B.
§Kaplan-Meier method.
¶Confirmed no sooner than 4 weeks after initial observation.
Pearson 2 test.
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 5.7% than in those with levels less than 5.7% in both treatment arms.
Median OS was approximately 1.5 months shorter in the figitumumab
arm than in the control arm, regardless of baseline HbA1c (HR: patients
with low HbA1c, 1.07; patients with high levels, 1.26).
Beyond the failure to demonstrate efficacy, a worrisome finding
of this study was the relatively high frequency of treatment-related
deaths associated with figitumumab (5%), an effect that was not
detected in the phase II study. There are a number of potential reasons
that may provide insight for future clinical trial design, dosing levels,
and anticipation and management of toxicities, particularly where
combination regimens are involved. First, only about half of the 98
patients randomly assigned to figitumumab in the phase II trial re-
ceived the 20 mg/kg dose, a sample that might have been too small to
detect safety signals. However, the incidence of grade 3/4 hyperglyce-
mia was greater in the phase II study (20%) than in our current study
(12%).8 Second, there were inherent differences in the patient popu-
lations. For example, the phase III study enrolled patients with pre-
dominantly squamous cell histology and far more current smokers
(42% v 13%) than the phase II study. Hence, the phase III patient
population may have had more attendant comorbidities (latent or
overt), which might have rendered them more vulnerable to toxicity
or intercurrent grade 5 events. Third, the phase II trial was conducted
almost exclusively at tertiary referral centers, which may have led to
subtle differences in the types of patients enrolled and how they were
managed. As several study centers in the phase III trial enrolled only a
few patients each, the investigators may have initially lacked
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Fig 2. Kaplan-Meier estimates of (A) overall survival (OS) and (B) progression-free survival (PFS) in the randomly assigned population. HR, hazard ratio.
Favors figitumumab Favors control
Factor n HR 95% CI Natural log HR (95% CI)
 
Overall 681 1.18 0.99 to 1.40
 
Sex
  Female 159 1.09 0.75 to 1.60
  Male 522 1.20 0.99 to 1.46
 
ECOG PS
  0 228 0.99 0.73 to 1.34
  1 443 1.21 0.98 to 1.50
 
Nonsquamous
  Yes 79 1.18 0.71 to 1.96
  No 602 1.16 0.96 to 1.39
 
Smoker 
  Never 67 1.46 0.83 to 2.57
  Current 283 1.11 0.85 to 1.45
 
Stage
  IIIB 78 1.28 0.75 to 2.19
  IV 602 1.16 0.97 to 1.40
 
HbA1c
  < 5.7% 267 1.07 0.81 to 1.41
  ≥ 5.7% 371 1.26 1.00 to 1.60
–0.6 –0.4 –0.2 0 0.2 0.4 0.6 0.8 1.0 1.2
Fig 3. Forest plot of overall survival by
selected baseline characteristics. ECOG
PS, Eastern Cooperative Oncology Group
performance status; HbA1c, glycosylated
hemoglobin; HR, hazard ratio.
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experience in managing figitumumab complications such as hyper-
glycemia and dehydration.
Furthermore, although patient and disease characteristics were
well balanced between arms, we cannot exclude the possibility that
minor baseline demographic imbalances in this study might have
produced inconsistent results. Although figitumumab was combined
with the same full-dose chemotherapy doublet as in the phase II study,
lower doses of the doublet might have improved the tolerability of the
combination. Finally, the difference in the incidence of treatment-
related grade 5 AEs between the figitumumab and control arms (5% v
1%), may indicate that signaling through IGF-1R and its attendant
pathways is critical in maintaining homeostasis, such that inhibition
significantly disrupts the insulin receptor/IGF-1R/growth-hormone
signaling axis. This concern may be heightened in patients with ad-
vanced squamous cell NSCLC, who often have multiple comorbidities
and who constituted the vast majority of participants in this trial. Our
experience highlights the potential discrepancies between phase II and
phase III trials in both safety and efficacy, and underscores the impor-
tance of identifying a priori the patient population(s) most likely to
benefit from therapy. However, as seen in our current study, inclusion
of such a selected patient group (predominantly squamous cell
NSCLC) does not guarantee improved safety or efficacy.
In conclusion, though the phase II trial suggested an ORR advan-
tage for adding figitumumab to standard chemotherapy in advanced
NSCLC, our current phase III study involving nonadenocarcinoma
patients failed to show any benefit and unexpectedly suggested a
possible detrimental effect. This may be a class effect and should be
assessed in current and future trials examining IGF-1R inhibitors.
Further clinical development of figitumumab is not being pursued.
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Table A1. Boundaries for the Planned Interim Analyses and First Interim Analysis Results
Analysis
No. of
Events
Efficacy Boundaries for
Rejecting the Null Hypothesis
Futility Boundaries for Rejecting
the Alternative Hypothesis
Z Score Hazard Ratio Z Score Hazard Ratio
Plan for first interim analysis 216 3.710 0.603 0.695 1.10
Plan for second interim analysis 433 2.511 0.785 1.003 0.908
Plan for final analysis 649 1.993 0.855
Computed boundaries for actual first interim analysis 225 3.632 0.616 0.595 1.083
Observed results for first interim analysis 225 1.407† 1.209†
Hazard ratio was computed from z score boundary assuming proportional hazards and approximating the SE using the No. of events. Decisions were based on
the z score boundaries.
†Based on interim data.
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Table A2. Grade 5 All-Causality Adverse Events, Excluding Disease Progression
Adverse Event
Figitumumab Arm (n  338) Control Arm (n  333)
No. of Patients % No. of Patients %
Total 43 13 32 10
Pulmonary hemorrhage 7 2 4 1
Pneumonia 7 2 3 1
Cardiopulmonary failure 5 1 2 1
Sepsis 4 1 1  1
Death 3 1 3 1
Pulmonary embolism 1  1 3 1
Respiratory failure 2 1 1  1
Renal failure 2 1 1  1
Cerebrovascular accident 0 3 1
Gastrointestinal hemorrhage 0 2 1
Cardiovascular disorder 2 1 0
Hemorrhage 2 1 0
Sudden death 1  1 1  1
Performance status decreased 1  1 1  1
Arrhythmia 1  1 0
Emphysema 1  1 0
Hypovolemic shock 1  1 0
Hypoxia 1  1 0
Myocardial infarction 1  1 0
Multiorgan failure 1  1 0
Neutropenia 1  1 0
Neutropenic sepsis 1  1 0
Staphylococcal infection 1  1 0
Toxicity to various agents 1  1 0
Asphyxia 0 1  1
Cardiac failure 0 1  1
Dehydration 0 1  1
Dyspnea 0 1  1
Pulmonary edema 0 1  1
Suicide 0 1  1
Superior vena cava syndrome 0 1  1
P  .22 by two-sided Fisher’s exact test. Some patients had more than one grade 5 adverse event.
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Figitumumab
Control
No. at risk
Figitumumab 193 153 116 86 65 52 41 36 19 13 6 0
Control 182 157 138 108 88 67 60 51 30 21 6 2 0
No. at risk
Figitumumab 120 100 82 73 56 42 36 31 26 19 8 4 1 0
Control 96 85 72 57 40 33 27 23 16 10 5 1 0
Fig A1. Kaplan-Meier estimates of overall survival (OS) in patients with (A) total baseline insulin-like growth factor 1 (IGF-1) less than 120 ng/mL or (B) total baseline
IGF-1  120 ng/mL. HR, hazard ratio.
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